(Q57225860)

English

Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment

No description defined

In more languages

Statements

scholarly article

0 references

Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment (English)

0 references

1 reference

based on heuristic

inferred from title

author name string

In Hae Park

1

0 references

Jungsil Ro

2

0 references

Sohee Park

3

0 references

Hyeong-Seok Lim

4

0 references

Keun Seok Lee

5

0 references

Han Sung Kang

6

0 references

So-Youn Jung

7

0 references

Seeyeon Lee

8

0 references

language of work or name

0 references

publication date

January 2012

0 references

Breast Cancer Research and Treatment

0 references

131

0 references

2

0 references

455-61

0 references

https://scigraph.springernature.com/pub.10.1007/s10549-011-1425-2

0 references

A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

Pharmacogenetics in breast cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

Impaired tamoxifen metabolism reduces survival in familial breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

Genotype-guided tamoxifen therapy: time to pause for reflection?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

CYP2D6 genotyping by a multiplex primer extension reaction.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

Association between CYP2D6 polymorphisms and breast cancer outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1425-2

21 January 2018

Identifiers

10.1007/S10549-011-1425-2

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57225860&oldid=1962117885"